Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation

EMBO Journal

Volumn 35, Issue 5, 2016, Pages 462-478

  Kim, Min Hwan ^a   Kim, Jongshin ^a   Hong, Hyowon ^a   Lee, Si Hyung ^a   Lee, June Koo ^a   Jung, Eunji ^a   Kim, Joon ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

actin cytoskeleton; BRAF inhibitor resistance; melanoma; TAZ; YAP

Indexed keywords

ACTIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; MYC PROTEIN; MYOSIN ADENOSINE TRIPHOSPHATASE; PROTEIN TESK1; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SOX10; TRANSCRIPTION FACTOR TAZ; TRANSCRIPTION FACTOR YAP1; UNCLASSIFIED DRUG; VEMURAFENIB; B RAF KINASE; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; PHOSPHOPROTEIN; PROTEIN KINASE INHIBITOR; RNA; SIGNAL PEPTIDE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SULFONAMIDE; WWTR1 PROTEIN, HUMAN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ACTIN FILAMENT; ACTIN POLYMERIZATION; ARPC1B GENE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOARCHITECTURE; DRUG RESISTANCE; FMN2 GENE; GENE EXPRESSION; GENE SILENCING; MELANOMA CELL; MICROARRAY ANALYSIS; MYH10 GENE; MYH9 GENE; MYO5A GENE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STRESS FIBER; SVIL GENE; ANTAGONISTS AND INHIBITORS; CELL SHAPE; CELL SURVIVAL; DNA MICROARRAY; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENETICS; HUMAN; MELANOMA; METABOLISM; MUTATION; TUMOR CELL LINE;

ACTIN CYTOSKELETON; ACTINS; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL LINE, TUMOR; CELL SHAPE; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; HUMANS; INDOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MELANOMA; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHOPROTEINS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RNA; SULFONAMIDES;

EID: 84959345677     PISSN: 02614189     EISSN: 14602075     Source Type: Journal    
DOI: 10.15252/embj.201592081     Document Type: Article

References (49)

1. Anastas JN, Kulikauskas RM, Tamir T, Rizos H, Long GV, von Euw EM, Yang PT, Chen HW, Haydu L, Toroni RA, Lucero OM, Chien AJ, Moon RT, (2014) WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors. J Clin Investig 124: 2877-2890
2. Aragona M, Panciera T, Manfrin A, Giulitti S, Michielin F, Elvassore N, Dupont S, Piccolo S, (2013) A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell 154: 1047-1059
3. Butcher DT, Alliston T, Weaver VM, (2009) A tense situation: forcing tumour progression. Nat Rev Cancer 9: 108-122
4. Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins RP, Chaudhry SI, Harrington K, Williamson P, Moeendarbary E, Charras G, Sahai E, (2013) Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol 15: 637-646
5. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N, (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2: 401-404
6. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, et al, (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516
7. Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR, Poletti A, Daidone MG, Dupont S, Basso G, Bicciato S, Piccolo S, (2011) The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 147: 759-772
8. Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, Zanconato F, Le Digabel J, Forcato M, Bicciato S, Elvassore N, Piccolo S, (2011) Role of YAP/TAZ in mechanotransduction. Nature 474: 179-183
9. Edgar R, Domrachev M, Lash AE, (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207-210
10. Feng X, Degese MS, Iglesias-Bartolome R, Vaque JP, Molinolo AA, Rodrigues M, Zaidi MR, Ksander BR, Merlino G, Sodhi A, Chen Q, Gutkind JS, (2014) Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell 25: 831-845
11. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N, (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6: pl1
12. Girotti MR, Pedersen M, Sanchez-Laorden B, Viros A, Turajlic S, Niculescu-Duvaz D, Zambon A, Sinclair J, Hayes A, Gore M, Lorigan P, Springer C, Larkin J, Jorgensen C, Marais R, (2013) Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov 3: 158-167
13. Halder G, Dupont S, Piccolo S, (2012) Transduction of mechanical and cytoskeletal cues by YAP and TAZ. Nat Rev Mol Cell Biol 13: 591-600
14. Hirata E, Girotti MR, Viros A, Hooper S, Spencer-Dene B, Matsuda M, Larkin J, Marais R, Sahai E, (2015) Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin beta1/FAK Signaling. Cancer Cell 27: 574-588
15. Jaalouk DE, Lammerding J, (2009) Mechanotransduction gone awry. Nat Rev Mol Cell Biol 10: 63-73
16. Kapoor A, Yao W, Ying H, Hua S, Liewen A, Wang Q, Zhong Y, Wu CJ, Sadanandam A, Hu B, Chang Q, Chu GC, Al-Khalil R, Jiang S, Xia H, Fletcher-Sananikone E, Lim C, Horwitz GI, Viale A, Pettazzoni P, et al, (2014) Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell 158: 185-197
17. Kielbasa SM, Klein H, Roider HG, Vingron M, Bluthgen N, (2010) TransFind-predicting transcriptional regulators for gene sets. Nucleic Acids Res 38: W275-W280
18. Kim J, Jo H, Hong H, Kim MH, Kim JM, Lee JK, Heo WD, Kim J, (2015) Actin remodelling factors control ciliogenesis by regulating YAP/TAZ activity and vesicle trafficking. Nat Commun 6: 6781
19. Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, et al, (2015) The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet 47: 250-256
20. Mana-Capelli S, Paramasivam M, Dutta S, McCollum D, (2014) Angiomotins link F-actin architecture to Hippo pathway signaling. Mol Biol Cell 25: 1676-1685
21. Matsui Y, Lai ZC, (2013) Mutual regulation between Hippo signaling and actin cytoskeleton. Protein Cell 4: 904-910
22. Mohseni M, Sun J, Lau A, Curtis S, Goldsmith J, Fox VL, Wei C, Frazier M, Samson O, Wong KK, Kim C, Camargo FD, (2014) A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway. Nat Cell Biol 16: 108-117
23. Moroishi T, Hansen CG, Guan KL, (2015) The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer 15: 73-79
24. Nallet-Staub F, Marsaud V, Li L, Gilbert C, Dodier S, Bataille V, Sudol M, Herlyn M, Mauviel A, (2014) Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in cutaneous melanoma. J Invest Dermatol 134: 123-132
25. Nguyen TV, Sleiman M, Moriarty T, Herrick WG, Peyton SR, (2014) Sorafenib resistance and JNK signaling in carcinoma during extracellular matrix stiffening. Biomaterials 35: 5749-5759
26. Olson EN, Nordheim A, (2010) Linking actin dynamics and gene transcription to drive cellular motile functions. Nat Rev Mol Cell Biol 11: 353-365
27. Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A, Reinhart-King CA, Margulies SS, Dembo M, Boettiger D, Hammer DA, Weaver VM, (2005) Tensional homeostasis and the malignant phenotype. Cancer Cell 8: 241-254
28. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, et al, (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480: 387-390
29. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R, (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483: 100-103
30. Pritchard CA, Hayes L, Wojnowski L, Zimmer A, Marais RM, Norman JC, (2004) B-Raf acts via the ROCKII/LIMK/cofilin pathway to maintain actin stress fibers in fibroblasts. Mol Cell Biol 24: 5937-5952
31. Rizos H, Menzies AM, Pupo GM, Carlino MS, Fung C, Hyman J, Haydu LE, Mijatov B, Becker TM, Boyd SC, Howle J, Saw R, Thompson JF, Kefford RF, Scolyer RA, Long GV, (2014) BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res 20: 1965-1977
32. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, et al, (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372: 30-39
33. Sahai E, Olson MF, Marshall CJ, (2001) Cross-talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motility. EMBO J 20: 755-766
34. Sakurai K, Talukdar I, Patil VS, Dang J, Li Z, Chang KY, Lu CC, Delorme-Walker V, Dermardirossian C, Anderson K, Hanein D, Yang CS, Wu D, Liu Y, Rana TM, (2014) Kinome-wide functional analysis highlights the role of cytoskeletal remodeling in somatic cell reprogramming. Cell Stem Cell 14: 523-534
35. Sanchez-Laorden B, Viros A, Girotti MR, Pedersen M, Saturno G, Zambon A, Niculescu-Duvaz D, Turajlic S, Hayes A, Gore M, Larkin J, Lorigan P, Cook M, Springer C, Marais R, (2014) BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling. Sci Signal 7: ra30
36. Sanz-Moreno V, Gadea G, Ahn J, Paterson H, Marra P, Pinner S, Sahai E, Marshall CJ, (2008) Rac activation and inactivation control plasticity of tumor cell movement. Cell 135: 510-523
37. Shao DD, Xue W, Krall EB, Bhutkar A, Piccioni F, Wang X, Schinzel AC, Sood S, Rosenbluh J, Kim JW, Zwang Y, Roberts TM, Root DE, Jacks T, Hahn WC, (2014) KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 158: 171-184
38. Sharma S, Santiskulvong C, Rao J, Gimzewski JK, Dorigo O, (2014) The role of Rho GTPase in cell stiffness and cisplatin resistance in ovarian cancer cells. Integr Biol 6: 611-617
39. Su F, Bradley WD, Wang Q, Yang H, Xu L, Higgins B, Kolinsky K, Packman K, Kim MJ, Trunzer K, Lee RJ, Schostack K, Carter J, Albert T, Germer S, Rosinski J, Martin M, Simcox ME, Lestini B, Heimbrook D, et al, (2012) Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res 72: 969-978
40. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP, (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102: 15545-15550
41. Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, Haanen J, Blank C, Wesseling J, Willems SM, Zecchin D, Hobor S, Bajpe PK, Lieftink C, Mateus C, Vagner S, Grernrum W, Hofland I, Schlicker A, Wessels LF, et al, (2014) Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 508: 118-122
42. Thery M, (2010) Micropatterning as a tool to decipher cell morphogenesis and functions. J Cell Sci 123: 4201-4213
43. Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, Place CS, Taylor-Weiner A, Whittaker S, Kryukov GV, Hodis E, Rosenberg M, McKenna A, Cibulskis K, Farlow D, Zimmer L, Hillen U, Gutzmer R, Goldinger SM, Ugurel S, et al, (2014) The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 4: 94-109
44. Vogel V, Sheetz M, (2006) Local force and geometry sensing regulate cell functions. Nat Rev Mol Cell Biol 7: 265-275
45. Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH, Zhao J, Yuan H, Tumaneng K, Li H, Fu XD, Mills GB, Guan KL, (2012) Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 150: 780-791
46. Zhao B, Li L, Lu Q, Wang LH, Liu CY, Lei Q, Guan KL, (2011a) Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev 25: 51-63
47. Zhao B, Li L, Wang L, Wang CY, Yu J, Guan KL, (2012) Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev 26: 54-68
48. Zhao B, Tumaneng K, Guan KL, (2011b) The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol 13: 877-883
49. Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, Lauwers GY, Thasler W, Lee JT, Avruch J, Bardeesy N, (2009) Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 16: 425-438